ZOONO GROUP LIMITED — Capital/Financing Update 2021

Mar 31, 2021

==> picture [130 x 28] intentionally omitted <==

Zoono Group Limited (ASX: ZNO) ASX ANNOUNCEMENT

1 April 2021

Company Update

Highlights:

• Zoono Microbe Shield successfully tested in the USA against Human Coronavirus 229E

• New Distributors appointed / New Supply Agreements.

• Update on December Quarter

• Boeing partners with Zoono to distribute Microbe Shield to airlines globally.

• Fine Hygienic Paper LLC on track to meet projected US$7M sales over next 6 months.

• Production & IP Protection Update

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on significant, recent developments:

Microbe Shield successfully tests against Human Coronavirus 229E

While Zoono's Microbe Shield surface sanitiser and GermFree24 hand sanitiser products have previously been successfully tested against the nominated COVID surrogate feline coronavirus, Zoono is pleased to advise that its flagship product, Zoono Microbe Shield, has now been successfully tested against the Human Coronavirus 229E and now meets the US EPA Standard ASTM E1053.

Testing was completed by New Jersey based Nelson Laboratories – an independent Laboratory operating under US FDA (GMP) regulations.

New Distributors / New Supply Agreement

Subsequent to gaining regulatory approvals, Zoono has appointed new distribution partners in Norway, Luxembourg, Greece and Poland. Initial orders are pending in each country.

After an extensive market evaluation, Microsoft has invited Zoono to become an approved supplier to their office network. The initial purchase has been received for their Redmond Campus (comprising 125 buildings and 53,500 staff in Washington

ZOONO GROUP LIMITED Address : Level 12, 225 George Street, Sydney NSW 2000 ABN: 73 006 645 754 · Web: www.zoono.com

State, USA), with the US rollout to commence following the return of staff to the Campus in May.

The initial shipment of Zoono products to Russia has also been completed. Significant monthly orders are scheduled to follow, in line with their contract[1] .

Update on December Quarter

Zoono had previously reported that, as at 31 December 2020, it had invoiced sales on hand of $7 Million[2] . Despite global freight and logistic challenges, in excess of $5 Million (unaudited) has now been shipped in Q3 FY21. This is in addition to new sales in the quarter.

Boeing partners with Zoono to distribute Microbe Shield to airlines globally.

Aircraft manufacturer Boeing has partnered with Zoono to offer Zoono products to airlines globally. Microbe Shield meets Boeing Specification Standard BSS7434 for use in aircraft interiors and is now available from the official Boeing on-line store.

FHH on track to meet US$7M sales projections for 6 months.

Fine Hygiene Group LLC ( FHH ) is on track to meet its sales projections of US$7 Million over the next 6 months[3] . Currently selling in three countries only, FHH is scheduled to expand into new territories (including Europe, USA and Australia) as soon as the relevant regulatory requirements are satisfied.

Production & IP Protection Update

Zoono has now brought the production of its plastic bottles ‘inhouse’. This will reduce its dependence on global suppliers and remove one of the production bottlenecks experienced during 2020. Zoono expects to commence the production of 1 Million bottles in the near future.

In order to further protect Zoono’s unique technology, Zoono has recently lodged further global patent applications in relation to formulations / specialised applications. To keep up to date with what is happening globally on a day-to-day basis, follow Zoono Global on Linkedin at https://www.linkedin.com/company/zoono/.

1 See announcement dated 16 December 2020 for further information.

2 Zoono refers to “invoiced sales” when an order is received from a customer. A sale is only recorded as revenue once the product is despatched to the customer.

3 See announcement dated 16 December 2020 for further information.

Zoono Group Limited (ASX:ZNO) · Level 12, 225 George Street, Sydney NSW 2000 · ABN: 73 006 645 754 · www.zoono.com

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop Paul Ravlich Group Managing Director/CEO Group CFO M: +64 21 659977 M: +64 21 0759176 E: paul.hyslop@zoono.com. E: paul.ravlich@zoono.com.

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally friendly antimicrobial solutions. Zoono’s mission is to improve health and well-being through innovative, safe, nontoxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the ‘Zoono molecule’, a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono’s products have received numerous regulatory approvals and the company’s technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com

Zoono Group Limited (ASX:ZNO) · Level 12, 225 George Street, Sydney NSW 2000 · ABN: 73 006 645 754 · www.zoono.com